Payment overview · 2025
General Payments
$861.26
53 reported records · 10 companies
Healthcare provider profile · identity verified
Stephan Michael Moss
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · BRIGHAM CITY, UT · NPI 1063906857
Verified facts
What the public records show
CMS Open Payments records show Stephan Michael Moss received $861.26 in general payments during 2025 across 53 reported records.
ABBVIE INC. accounted for 33.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $284.81 | 33.1% | 24 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $221.15 | 25.7% | 18 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $157.83 | 18.3% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $82.32 | 9.6% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $30.84 | 3.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.86 | 2.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.00 | 2.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.87 | 1.6% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $13.56 | 1.6% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $12.02 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $861.26 | 53 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $157.83 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $157.44 | 14 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $114.83 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $108.99 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $105.54 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $105.54 | 9 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $82.32 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $80.19 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $68.75 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $68.75 | 1 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $35.42 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $30.84 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.86 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.00 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $22.00 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $13.87 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $13.56 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $12.02 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $6.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 273 | 61 |
| Atorvastatin Calcium | Atorvastatin Calcium | 165 | 42 |
| Metformin Hcl | Metformin Hcl | 163 | 34 |
| Azithromycin | Azithromycin | 157 | 107 |
| Gabapentin | Gabapentin | 153 | 32 |
| Lisinopril | Lisinopril | 153 | 40 |
| Simvastatin | Simvastatin | 151 | 42 |
| Omeprazole | Omeprazole | 130 | 40 |
| Amlodipine Besylate | Amlodipine Besylate | 127 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 126 | 23 |
| Lorazepam | Lorazepam | 114 | 13 |
| Montelukast Sodium | Montelukast Sodium | 108 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 99 | 30 |
| Propranolol Hcl | Propranolol Hcl | 92 | 17 |
| Glimepiride | Glimepiride | 89 | 25 |
| Losartan Potassium | Losartan Potassium | 86 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 82 | 25 |
| Clonazepam | Clonazepam | 78 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 74 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 74 | 16 |
| Alprazolam | Alprazolam | 73 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 71 | 15 |
| Sertraline Hcl | Sertraline Hcl | 70 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 68 | 16 |
| Tramadol Hcl | Tramadol Hcl | 67 | 22 |
| Meloxicam | Meloxicam | 66 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 65 | 29 |
| Trazodone Hcl | Trazodone Hcl | 63 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 58 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 53 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 52 | suppressed |
| Furosemide | Furosemide | 50 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 49 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 49 | 13 |
| Potassium Chloride | Potassium Chloride | 46 | 14 |
| Testosterone Cypionate | Testosterone Cypionate | 46 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 41 | 14 |
| Prednisone | Prednisone | 41 | 32 |
| Ozempic | Semaglutide | 40 | suppressed |
| Diazepam | Diazepam | 38 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 36 | 20 |
| Eliquis | Apixaban | 34 | suppressed |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Carvedilol | Carvedilol | 27 | suppressed |
| Estradiol | Estradiol | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Ofloxacin | Ofloxacin | 26 | 25 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 24 |
| Promethazine Hcl | Promethazine Hcl | 25 | 11 |
| Cephalexin | Cephalexin | 24 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | 16 |
| Finasteride | Finasteride | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 19 |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 23 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Allopurinol | Allopurinol | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 19 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 19 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Bicalutamide | Bicalutamide | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Dexamethasone | Dexamethasone | 11 | suppressed |
| Dexmethylphenidate Hcl Er | Dexmethylphenidate Hcl | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $861.26 · 53 records | ABBVIE INC. | AIRSUPRA, BREZTRI, CAPLYTA, EVENITY, FARXIGA, FREESTYLE LIBRE 3, Kerendia, NEXPLANON, NURTEC ODT, OTEZLA, PROLIA, QULIPTA, REPATHA, REXULTI, TAVNEOS, UBRELVY, VRAYLAR, Veozah, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Vraylar play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error